View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsEcofibre 将来の成長Future 基準チェック /06現在、 Ecofibreの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長49.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Mar 19Ecofibre Limited Announces Chief Financial Officer Changes, Effective March 24, 2025Ecofibre Limited announced the retirement of Jonathan Brown and the appointment of Amy Elizabeth Donley as Chief Financial Officer (CFO) of Ecofibre, effective March 24, 2025. Amy is a dynamic finance leader with a track record of driving successful C-suite financial performance, and developing and implementing commercial strategy and business improvement plans in both large corporate and smaller entrepreneurial companies. She has extensive experience in technical accounting (IFRS and US GAAP), ERP implementations and working within regulated industries. Amy is based in North Carolina and is passionate about sustainability and the opportunities for Ecofibre as the market for sustainable solutions continues to grow. Amy replaces Jonathan Brown as CFO, as Jonathan retires from Ecofibre after many years of service. There will be a one-month transition period.お知らせ • Feb 14Ecofibre Limited to Report First Half, 2025 Results on Feb 19, 2025Ecofibre Limited announced that they will report first half, 2025 results on Feb 19, 2025お知らせ • Sep 02Ecofibre Limited, Annual General Meeting, Oct 16, 2024Ecofibre Limited, Annual General Meeting, Oct 16, 2024.Reported Earnings • Aug 29Full year 2024 earnings released: AU$0.11 loss per share (vs AU$0.12 loss in FY 2023)Full year 2024 results: AU$0.11 loss per share (improved from AU$0.12 loss in FY 2023). Revenue: AU$28.0m (down 14% from FY 2023). Net loss: AU$38.2m (loss narrowed 4.3% from FY 2023). Over the last 3 years on average, the company's earnings growth rate has exceeded its share price growth rate by 2 percentage points per year.New Risk • May 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$12m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 71% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (8.9% increase in shares outstanding). Market cap is less than US$100m (AU$17.9m market cap, or US$11.8m).お知らせ • Mar 28Elixinol Wellness Limited (ASX:EXL) completed the acquisition of Ananda Food Pty Ltd from Ecofibre Limited (ASX:EOF).Elixinol Wellness Limited (ASX:EXL) entered into Conditional agreement to acquire Ananda Food Pty Ltd from Ecofibre Limited (ASX:EOF) for AUD 3 million on February 12, 2024. Under the terms of agreement, Elixinol Wellness will pay AUD 2 million as upfront payment and AUD 1 million as earnout consideration. Elixinol Wellness Limited will raise AUD 3.16 million through Rights Issue Offer which will be used in part to finance the acquisition. The deal is expected to be completed by the end of March, 2024. Completion of the Ananda Food acquisition is conditional on raising sufficient funds under the Rights Issue Offer and the satisfaction of a number of customary conditions. As of March 20, 2024, the transaction is expected to close on March 28, 2024. Elixinol Wellness Limited (ASX:EXL) completed the acquisition of Ananda Food Pty Ltd from Ecofibre Limited (ASX:EOF) on March 28, 2024. Ron Dufficy will now be stepping down from the role of Group Chief Executive Officer and Natalie Butler will join the EXL Board.New Risk • Feb 25New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$6.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$6.9m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 66% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (8.9% increase in shares outstanding). Market cap is less than US$100m (AU$31.1m market cap, or US$20.4m).お知らせ • Feb 20Ecofibre Limited to Report First Half, 2024 Results on Feb 23, 2024Ecofibre Limited announced that they will report first half, 2024 results on Feb 23, 2024お知らせ • Feb 14Elixinol Wellness Limited (ASX:EXL) entered into Conditional agreement to acquire Ananda Food Pty Ltd from Ecofibre Limited (ASX:EOF) for AUD 3 million.Elixinol Wellness Limited (ASX:EXL) entered into Conditional agreement to acquire Ananda Food Pty Ltd from Ecofibre Limited (ASX:EOF) for AUD 3 million on February 12, 2024. The deal is expected to be completed by the end of March, 2024.お知らせ • Jan 30Ecofibre Limited Receives a Notice from Phil Warner Pty LtdOn January 30, 2024, Ecofibre Limited announced that it had received a notice on January 17, 2024, under section 249D of the Corporations Act 2001, from Phil Warner Pty Ltd to consider a resolution to appoint Alexander James Goff Keach as a director of the Company at a general meeting of the Company to be held on February 28, 2024. Additionally, the Board recommends that the shareholders to vote against the resolution.お知らせ • Nov 29Ecofibre Limited Announces CEO ChangesEcofibre Limited announced that their long-standing CEO, Eric Wang, has tendered his resignation, and the Ecofibre Board has accepted his resignation effective immediately. Eric Wang joined Ecofibre in 2016 as CFO and Executive Director. Vanessa Wallace will act as interim CEO, and Ecofibre will commence a comprehensive search and make further announcements as appropriate.お知らせ • Oct 05Ecofibre Limited, Annual General Meeting, Nov 23, 2023Ecofibre Limited, Annual General Meeting, Nov 23, 2023, at 11:01 AUS Eastern Standard Time.Reported Earnings • Oct 01Full year 2023 earnings released: AU$0.12 loss per share (vs AU$0.044 loss in FY 2022)Full year 2023 results: AU$0.12 loss per share (further deteriorated from AU$0.044 loss in FY 2022). Revenue: AU$32.5m (up 7.6% from FY 2022). Net loss: AU$39.9m (loss widened 172% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 44 percentage points per year, which is a significant difference in performance.New Risk • Sep 02New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$8.6m free cash flow). Share price has been highly volatile over the past 3 months (32% average weekly change). Earnings have declined by 53% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (8.3% increase in shares outstanding). Market cap is less than US$100m (AU$65.4m market cap, or US$42.2m).Reported Earnings • Aug 23Full year 2023 earnings released: AU$0.12 loss per share (vs AU$0.044 loss in FY 2022)Full year 2023 results: AU$0.12 loss per share (further deteriorated from AU$0.044 loss in FY 2022). Revenue: AU$32.5m (up 7.6% from FY 2022). Net loss: AU$39.9m (loss widened 172% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 44 percentage points per year, which is a significant difference in performance.お知らせ • Aug 18Ecofibre Limited to Report Fiscal Year 2023 Results on Aug 22, 2023Ecofibre Limited announced that they will report fiscal year 2023 results on Aug 22, 2023Recent Insider Transactions • Mar 22CEO, MD & Director recently bought AU$58k worth of stockOn the 15th of March, Eric Wang bought around 289k shares on-market at roughly AU$0.20 per share. This transaction amounted to 1.9% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Eric has been a buyer over the last 12 months, purchasing a net total of AU$249k worth in shares.Board Change • Feb 22High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. CEO, MD & Director Eric Wang is the most experienced director on the board, commencing their role in 2015. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 21First half 2023 earnings released: AU$0.052 loss per share (vs AU$0.02 loss in 1H 2022)First half 2023 results: AU$0.052 loss per share (further deteriorated from AU$0.02 loss in 1H 2022). Revenue: AU$16.5m (up 6.4% from 1H 2022). Net loss: AU$17.6m (loss widened 163% from 1H 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.お知らせ • Feb 20Jon Meadmore to Retire as A Non-Executive Director of Ecofibre LimitedEcofibre Limited announced that Jon Meadmore will retire as a non-executive director of the company as at the Half Year Results announcement on 20 February 2023. Meadmore has been on the Ecofibre Board since October 2017 and was the company's first non-executive director.お知らせ • Feb 16Ecofibre Limited to Report First Half, 2023 Results on Feb 20, 2023Ecofibre Limited announced that they will report first half, 2023 results on Feb 20, 2023Reported Earnings • Sep 28Full year 2022 earnings released: AU$0.044 loss per share (vs AU$0.022 loss in FY 2021)Full year 2022 results: AU$0.044 loss per share (further deteriorated from AU$0.022 loss in FY 2021). Revenue: AU$30.2m (up 5.0% from FY 2021). Net loss: AU$14.7m (loss widened 110% from FY 2021). Products in clinical trials Phase II: 4 Phase III: 1 Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 25Full year 2022 earnings released: AU$0.044 loss per share (vs AU$0.022 loss in FY 2021)Full year 2022 results: AU$0.044 loss per share (down from AU$0.022 loss in FY 2021). Revenue: AU$30.2m (up 5.0% from FY 2021). Net loss: AU$14.7m (loss widened 110% from FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.Board Change • Apr 02High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 2 experienced directors. No highly experienced directors. CEO, MD & Director Eric Wang is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Recent Insider Transactions • Mar 09CEO, MD & Director recently bought AU$435k worth of stockOn the 4th of March, Eric Wang bought around 1m shares on-market at roughly AU$0.43 per share. This was the largest purchase by an insider in the last 3 months. This was Eric's only on-market trade for the last 12 months.Board Change • Feb 02High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 2 experienced directors. No highly experienced directors. CEO, MD & Director Eric Wang is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Aug 05Full year 2021 earnings released: AU$0.022 loss per share (vs AU$0.044 profit in FY 2020)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2021 results: Revenue: AU$28.8m (down 43% from FY 2020). Net loss: AU$6.99m (down 153% from profit in FY 2020).Is New 90 Day High Low • Mar 02New 90-day low: AU$1.22The company is down 33% from its price of AU$1.83 on 02 December 2020. The Australian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 8.0% over the same period.Is New 90 Day High Low • Feb 20New 90-day low: AU$1.57The company is down 4.0% from its price of AU$1.64 on 20 November 2020. The Australian market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 30% over the same period.Recent Insider Transactions • Dec 18CEO, MD & Director recently bought AU$745k worth of stockOn the 11th of December, Eric Wang bought around 350k shares on-market at roughly AU$2.13 per share. This was the largest purchase by an insider in the last 3 months. This was Eric's only on-market trade for the last 12 months.Valuation Update With 7 Day Price Move • Dec 05Market bids up stock over the past weekAfter last week's 18% share price gain to AU$2.04, the stock is trading at a trailing P/E ratio of 46.9x, up from the previous P/E ratio of 39.6x. This compares to an average P/E of 46x in the Pharmaceuticals industry in Oceania. Total return to shareholders over the past year is a loss of 33%.Is New 90 Day High Low • Oct 21New 90-day low: AU$1.82The company is down 26% from its price of AU$2.46 on 22 July 2020. The Australian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period.Valuation Update With 7 Day Price Move • Oct 21Market pulls back on stock over the past weekAfter last week's 29% share price decline to AU$1.82, the stock is trading at a trailing P/E ratio of 41.3x, down from the previous P/E ratio of 58.4x. This compares to an average P/E of 41x in the Pharmaceuticals industry in Oceania. Total return to shareholders over the past year is a loss of 44%. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Ecofibre は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測CHIA:EOF - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202428-15-15-14N/A9/30/202428-29-16-14N/A6/30/202428-43-17-14N/A3/31/202427-54-15-11N/A12/31/202327-66-12-9N/A9/30/202329-52-10-8N/A6/30/202331-38-9-7N/A3/31/202330-31-11-9N/A12/31/202230-24-13-11N/A9/30/202230-20-13-11N/A6/30/202230-15-13-11N/A3/31/202230-11-12-9N/A12/31/202130-8-11-8N/A9/30/202129-8-13-8N/A6/30/202129-7-14-8N/A3/31/202133-3-19-6N/A12/31/2020361-24-4N/A9/30/2020447-211N/A6/30/20205113-176N/A3/31/20205113-106N/A12/31/20195113-37N/A9/30/20194310-35N/A6/30/2019366-32N/A3/31/2019270-50N/A12/31/201818-7-7-3N/A9/30/201812-8N/A-5N/A6/30/20186-9N/A-7N/A6/30/20171-9N/A-7N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: EOFの予測収益成長が 貯蓄率 ( 3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: EOFの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: EOFの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: EOFの収益がAustralian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: EOFの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: EOFの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/07/28 00:56終値2025/04/30 00:00収益2024/12/31年間収益2024/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Ecofibre Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関William MacdiarmidOrd Minnett LimitedAlexander SmithPAC Partners Securities Pty. Ltd.
お知らせ • Mar 19Ecofibre Limited Announces Chief Financial Officer Changes, Effective March 24, 2025Ecofibre Limited announced the retirement of Jonathan Brown and the appointment of Amy Elizabeth Donley as Chief Financial Officer (CFO) of Ecofibre, effective March 24, 2025. Amy is a dynamic finance leader with a track record of driving successful C-suite financial performance, and developing and implementing commercial strategy and business improvement plans in both large corporate and smaller entrepreneurial companies. She has extensive experience in technical accounting (IFRS and US GAAP), ERP implementations and working within regulated industries. Amy is based in North Carolina and is passionate about sustainability and the opportunities for Ecofibre as the market for sustainable solutions continues to grow. Amy replaces Jonathan Brown as CFO, as Jonathan retires from Ecofibre after many years of service. There will be a one-month transition period.
お知らせ • Feb 14Ecofibre Limited to Report First Half, 2025 Results on Feb 19, 2025Ecofibre Limited announced that they will report first half, 2025 results on Feb 19, 2025
お知らせ • Sep 02Ecofibre Limited, Annual General Meeting, Oct 16, 2024Ecofibre Limited, Annual General Meeting, Oct 16, 2024.
Reported Earnings • Aug 29Full year 2024 earnings released: AU$0.11 loss per share (vs AU$0.12 loss in FY 2023)Full year 2024 results: AU$0.11 loss per share (improved from AU$0.12 loss in FY 2023). Revenue: AU$28.0m (down 14% from FY 2023). Net loss: AU$38.2m (loss narrowed 4.3% from FY 2023). Over the last 3 years on average, the company's earnings growth rate has exceeded its share price growth rate by 2 percentage points per year.
New Risk • May 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$12m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 71% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (8.9% increase in shares outstanding). Market cap is less than US$100m (AU$17.9m market cap, or US$11.8m).
お知らせ • Mar 28Elixinol Wellness Limited (ASX:EXL) completed the acquisition of Ananda Food Pty Ltd from Ecofibre Limited (ASX:EOF).Elixinol Wellness Limited (ASX:EXL) entered into Conditional agreement to acquire Ananda Food Pty Ltd from Ecofibre Limited (ASX:EOF) for AUD 3 million on February 12, 2024. Under the terms of agreement, Elixinol Wellness will pay AUD 2 million as upfront payment and AUD 1 million as earnout consideration. Elixinol Wellness Limited will raise AUD 3.16 million through Rights Issue Offer which will be used in part to finance the acquisition. The deal is expected to be completed by the end of March, 2024. Completion of the Ananda Food acquisition is conditional on raising sufficient funds under the Rights Issue Offer and the satisfaction of a number of customary conditions. As of March 20, 2024, the transaction is expected to close on March 28, 2024. Elixinol Wellness Limited (ASX:EXL) completed the acquisition of Ananda Food Pty Ltd from Ecofibre Limited (ASX:EOF) on March 28, 2024. Ron Dufficy will now be stepping down from the role of Group Chief Executive Officer and Natalie Butler will join the EXL Board.
New Risk • Feb 25New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$6.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$6.9m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 66% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (8.9% increase in shares outstanding). Market cap is less than US$100m (AU$31.1m market cap, or US$20.4m).
お知らせ • Feb 20Ecofibre Limited to Report First Half, 2024 Results on Feb 23, 2024Ecofibre Limited announced that they will report first half, 2024 results on Feb 23, 2024
お知らせ • Feb 14Elixinol Wellness Limited (ASX:EXL) entered into Conditional agreement to acquire Ananda Food Pty Ltd from Ecofibre Limited (ASX:EOF) for AUD 3 million.Elixinol Wellness Limited (ASX:EXL) entered into Conditional agreement to acquire Ananda Food Pty Ltd from Ecofibre Limited (ASX:EOF) for AUD 3 million on February 12, 2024. The deal is expected to be completed by the end of March, 2024.
お知らせ • Jan 30Ecofibre Limited Receives a Notice from Phil Warner Pty LtdOn January 30, 2024, Ecofibre Limited announced that it had received a notice on January 17, 2024, under section 249D of the Corporations Act 2001, from Phil Warner Pty Ltd to consider a resolution to appoint Alexander James Goff Keach as a director of the Company at a general meeting of the Company to be held on February 28, 2024. Additionally, the Board recommends that the shareholders to vote against the resolution.
お知らせ • Nov 29Ecofibre Limited Announces CEO ChangesEcofibre Limited announced that their long-standing CEO, Eric Wang, has tendered his resignation, and the Ecofibre Board has accepted his resignation effective immediately. Eric Wang joined Ecofibre in 2016 as CFO and Executive Director. Vanessa Wallace will act as interim CEO, and Ecofibre will commence a comprehensive search and make further announcements as appropriate.
お知らせ • Oct 05Ecofibre Limited, Annual General Meeting, Nov 23, 2023Ecofibre Limited, Annual General Meeting, Nov 23, 2023, at 11:01 AUS Eastern Standard Time.
Reported Earnings • Oct 01Full year 2023 earnings released: AU$0.12 loss per share (vs AU$0.044 loss in FY 2022)Full year 2023 results: AU$0.12 loss per share (further deteriorated from AU$0.044 loss in FY 2022). Revenue: AU$32.5m (up 7.6% from FY 2022). Net loss: AU$39.9m (loss widened 172% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 44 percentage points per year, which is a significant difference in performance.
New Risk • Sep 02New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$8.6m free cash flow). Share price has been highly volatile over the past 3 months (32% average weekly change). Earnings have declined by 53% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (8.3% increase in shares outstanding). Market cap is less than US$100m (AU$65.4m market cap, or US$42.2m).
Reported Earnings • Aug 23Full year 2023 earnings released: AU$0.12 loss per share (vs AU$0.044 loss in FY 2022)Full year 2023 results: AU$0.12 loss per share (further deteriorated from AU$0.044 loss in FY 2022). Revenue: AU$32.5m (up 7.6% from FY 2022). Net loss: AU$39.9m (loss widened 172% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 44 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 18Ecofibre Limited to Report Fiscal Year 2023 Results on Aug 22, 2023Ecofibre Limited announced that they will report fiscal year 2023 results on Aug 22, 2023
Recent Insider Transactions • Mar 22CEO, MD & Director recently bought AU$58k worth of stockOn the 15th of March, Eric Wang bought around 289k shares on-market at roughly AU$0.20 per share. This transaction amounted to 1.9% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Eric has been a buyer over the last 12 months, purchasing a net total of AU$249k worth in shares.
Board Change • Feb 22High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. CEO, MD & Director Eric Wang is the most experienced director on the board, commencing their role in 2015. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 21First half 2023 earnings released: AU$0.052 loss per share (vs AU$0.02 loss in 1H 2022)First half 2023 results: AU$0.052 loss per share (further deteriorated from AU$0.02 loss in 1H 2022). Revenue: AU$16.5m (up 6.4% from 1H 2022). Net loss: AU$17.6m (loss widened 163% from 1H 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 20Jon Meadmore to Retire as A Non-Executive Director of Ecofibre LimitedEcofibre Limited announced that Jon Meadmore will retire as a non-executive director of the company as at the Half Year Results announcement on 20 February 2023. Meadmore has been on the Ecofibre Board since October 2017 and was the company's first non-executive director.
お知らせ • Feb 16Ecofibre Limited to Report First Half, 2023 Results on Feb 20, 2023Ecofibre Limited announced that they will report first half, 2023 results on Feb 20, 2023
Reported Earnings • Sep 28Full year 2022 earnings released: AU$0.044 loss per share (vs AU$0.022 loss in FY 2021)Full year 2022 results: AU$0.044 loss per share (further deteriorated from AU$0.022 loss in FY 2021). Revenue: AU$30.2m (up 5.0% from FY 2021). Net loss: AU$14.7m (loss widened 110% from FY 2021). Products in clinical trials Phase II: 4 Phase III: 1 Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 25Full year 2022 earnings released: AU$0.044 loss per share (vs AU$0.022 loss in FY 2021)Full year 2022 results: AU$0.044 loss per share (down from AU$0.022 loss in FY 2021). Revenue: AU$30.2m (up 5.0% from FY 2021). Net loss: AU$14.7m (loss widened 110% from FY 2021). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.
Board Change • Apr 02High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 2 experienced directors. No highly experienced directors. CEO, MD & Director Eric Wang is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Recent Insider Transactions • Mar 09CEO, MD & Director recently bought AU$435k worth of stockOn the 4th of March, Eric Wang bought around 1m shares on-market at roughly AU$0.43 per share. This was the largest purchase by an insider in the last 3 months. This was Eric's only on-market trade for the last 12 months.
Board Change • Feb 02High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 2 experienced directors. No highly experienced directors. CEO, MD & Director Eric Wang is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Aug 05Full year 2021 earnings released: AU$0.022 loss per share (vs AU$0.044 profit in FY 2020)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2021 results: Revenue: AU$28.8m (down 43% from FY 2020). Net loss: AU$6.99m (down 153% from profit in FY 2020).
Is New 90 Day High Low • Mar 02New 90-day low: AU$1.22The company is down 33% from its price of AU$1.83 on 02 December 2020. The Australian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 8.0% over the same period.
Is New 90 Day High Low • Feb 20New 90-day low: AU$1.57The company is down 4.0% from its price of AU$1.64 on 20 November 2020. The Australian market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 30% over the same period.
Recent Insider Transactions • Dec 18CEO, MD & Director recently bought AU$745k worth of stockOn the 11th of December, Eric Wang bought around 350k shares on-market at roughly AU$2.13 per share. This was the largest purchase by an insider in the last 3 months. This was Eric's only on-market trade for the last 12 months.
Valuation Update With 7 Day Price Move • Dec 05Market bids up stock over the past weekAfter last week's 18% share price gain to AU$2.04, the stock is trading at a trailing P/E ratio of 46.9x, up from the previous P/E ratio of 39.6x. This compares to an average P/E of 46x in the Pharmaceuticals industry in Oceania. Total return to shareholders over the past year is a loss of 33%.
Is New 90 Day High Low • Oct 21New 90-day low: AU$1.82The company is down 26% from its price of AU$2.46 on 22 July 2020. The Australian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period.
Valuation Update With 7 Day Price Move • Oct 21Market pulls back on stock over the past weekAfter last week's 29% share price decline to AU$1.82, the stock is trading at a trailing P/E ratio of 41.3x, down from the previous P/E ratio of 58.4x. This compares to an average P/E of 41x in the Pharmaceuticals industry in Oceania. Total return to shareholders over the past year is a loss of 44%.